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Abstract 
Childhood psychotic symptoms are associated with increased rates of schizophrenia, other psychiatric 
disorders, and suicide attempts in adulthood; thus, elucidating early risk indicators is crucial to target 
prevention efforts. There is considerable discordance for psychotic symptoms between monozygotic 
twins, indicating that child-specific non-genetic factors must be involved. Epigenetic processes may 
constitute one of these factors and have not yet been investigated in relation to childhood psychotic 
symptoms. Therefore, this study explored whether differences in DNA methylation at age 10 were 
associated with monozygotic twin discordance for psychotic symptoms at age 12. The Environmental Risk 
(E-Risk) Longitudinal Twin Study cohort of 2,232 children (1,116 twin pairs) was assessed for age-12 
psychotic symptoms and 24 monozygotic twin pairs discordant for symptoms were identified for 
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methylomic comparison. Children provided buccal samples at ages 5 and 10. DNA was bisulfite modified 
and DNA methylation was quantified using the Infinium HumanMethylation450 array. Differentially 
methylated positions (DMPs) associated with psychotic symptoms were subsequently tested in post-
mortem prefrontal cortex tissue from adult schizophrenia patients and age-matched controls. Site-specific 
DNA methylation differences were observed at age 10 between monozygotic twins discordant for age-12 
psychotic symptoms. Similar DMPs were not found at age 5. The top-ranked psychosis-associated DMP 
(cg23933044), located in the promoter of the C5ORF42 gene, was also hypomethylated in post-mortem 
prefrontal cortex brain tissue from schizophrenia patients compared to unaffected controls. These data 
tentatively suggest that epigenetic variation in peripheral tissue is associated with childhood psychotic 
symptoms and may indicate susceptibility to schizophrenia and other mental health problems. 
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Introduction 
Psychotic symptoms are reported by approximately 1 in 20 children at around 12 years of age
1
 and 
include paranoid thoughts, hearing or seeing things that others do not, and believing that others can read 
one‘s mind or vice versa. These symptoms often occur in children without a diagnosable illness but tend 
to be distressing
2
 and are highly predictive of schizophrenia, other psychiatric disorders, and suicide 
attempts in adulthood,
3
 as well as self-harm
1
 and suicide attempts
4
 in adolescence. Therefore, the 
etiology of these early psychotic symptoms requires further investigation. Understanding biological 
markers of childhood psychotic symptoms may facilitate the early detection of individuals at risk of 
developing severely disabling and life-threatening mental health problems and improve targeting of 
preventive interventions. Moreover, focusing on pre-clinical psychotic symptoms occurring early in life 
negates the effect of other potential confounders, including anti-psychotic medications, exposure to 
disorder-related traumatic events, such as forced hospitalization, and smoking, which are likely to 
influence epigenetic studies of adult schizophrenia patients.
5
 
Quantitative genetic studies of childhood psychotic symptoms demonstrate higher concordance 
rates in monozygotic (MZ) (43%) than dizygotic (DZ) (22%) twins, highlighting a significant genetic 
influence on these symptoms.
1
 Despite this, there is still considerable discordance for psychotic 
symptoms within MZ twin-pairs,
1,6
 indicating that child-specific non-genetic factors are also important in 
mediating their onset. Epigenetic processes may constitute such a factor. Recent studies have started to 
investigate the role of epigenetic processes—acting to developmentally regulate gene expression via 
DNA, histone proteins, and chromatin modifications—in complex disease phenotypes. Epigenetic 
variation identified in post-mortem brain tissue has been associated with several neuropsychiatric 
conditions, including schizophrenia and other psychotic disorders in adults.
7-10
 Moreover, DNA 
methylation differences in peripheral tissue have been found in individuals with schizophrenia compared 
to unaffected controls.
11-13
 
To date, epigenetic variation has not been explored in relation to childhood psychotic symptoms. 
Therefore, the aim of this study was to explore whether methylomic variation in early childhood 
(measured at ages 5 and 10) is associated with MZ twin discordance for psychotic symptoms at age 12. 
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The use of symptom-discordant MZ twins represents a powerful strategy in epigenetic epidemiology 
because identical twins are matched for genotype, age, sex, paternal age, population cohort effects, and 
exposure to several shared environmental factors.
14
 DNA methylation differences are detectable between 
MZ twins in early childhood
15
 and can change over a relatively short period of time,
15,16
 suggesting they 
may be markers of phenotypic variation. Indeed, DNA methylation differences in peripheral tissue 
samples have been associated with MZ twin discordance for several complex neuropsychiatric traits, 
including psychosis,
17
 autism,
18
 and depression.
19
 By utilizing prospectively collected epigenomic and 
phenotypic data we were able to examine the temporal relationship between epigenetic variation and 
onset of psychotic symptoms. Finally, given the tissue-specific nature of epigenetic processes, we aimed 
to explore whether differential methylation patterns associated with childhood psychotic symptoms in 
peripheral DNA samples reflect schizophrenia-associated variation in post-mortem brain tissue. 
Results 
DNA methylation differences at age 10 in MZ twins discordant for age-12 psychotic symptoms 
As expected, within-twin patterns of DNA methylation at age 10 were highly correlated across all MZ pairs 
(across all 391,565 probes included in the analysis, the average within-twin Pearson‘s r=0.98) and no 
difference in overall mean DNA methylation (calculated by averaging across all analyzed probes) was 
observed between affected and unaffected twins (P=0.61), indicating that childhood psychotic symptoms 
are not associated with any systemic changes in DNA methylation. In contrast, DNA methylation at 
individual CpG sites demonstrated considerable variability within discordant MZ twin pairs 
(supplementary figure 1B). Table 1 shows the top ten DMPs at age 10, which were associated with 
psychotic symptoms at age 12 (nominal P<5x10
-5
), with a more extensive list of DMPs (nominal P<0.001) 
given in supplementary table 1. The top-ranked DMPs were characterized by consistent psychosis-
associated within-pair differences in DNA methylation across the twin pairs (figure 1A). The top-ranked 
DMP, cg23933044, located in the promoter regulatory region of C5ORF42, was characterized by reduced 
DNA methylation in affected twins compared with their unaffected co-twins (mean Δβ=-0.034, P=6.76x10
-
7
) (figure 2A). The analyses were re-run for the top-ranked DMPs (P<5x10
-5
) adjusting for internalizing 
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and externalizing problems at age 10 and depression symptoms at age 12, with minimal effect on the 
reported associations (see supplementary table 2). 
We next tested the specificity of our psychosis-associated DMPs by comparing average within-
twin DNA methylation differences at the top ten loci in 20 age-matched concordant unaffected MZ twin 
pairs where neither twin had psychotic symptoms at age 12. DNA methylation data was available for 9/10 
top-ranked psychosis-associated DMPs. Average within-twin Δβ were significantly larger in the psychosis-
discordant twins compared to twins concordant for no psychotic symptoms (P<0.005 for all comparisons, 
see figure 1B). 
Gene ontology (GO) enrichment analysis identified 128 nominally significant enriched terms (see 
supplementary table 3 for genes included in the analysis) for the DMPs (P<0.001) identified in the age 
10 analysis, including several related to the etiology of psychosis, such as glutamatergic synaptic 
transmission (GO:0051966, P=0.0034) and neuron projection development (GO:0031175, P=0.0064). 
However, no enrichment term remained significant after Bonferroni correction for multiple testing. 
Investigating top-ranked age-10 DMPs in schizophrenia post-mortem brain tissue 
We examined DNA methylation at the top-ranked age-10 DMPs identified in our twin study (nominal 
P<5x10
-5
) in prefrontal cortex (PFC) samples from two independent cohorts of adult schizophrenia 
patients and matched non-psychiatric control samples (total n=38 schizophrenia and n=38 control 
samples; see supplementary table 4). The top-ranked DMP associated with childhood psychotic 
symptoms (cg2393304) was also significantly hypomethylated (Mean ∆β=-0.021, P=0.0005, Bonferroni 
adjusted P value=0.013) in a fixed-effects meta-analysis of the two independent PFC brain cohorts 
(figure 2). No significant differences in the PFC were observed for the other top-ranked age-10 
discordant-twin DMPs. 
DNA methylation differences at age 5 in discordant MZ twins 
We next assessed DNA methylation at age 5 in the majority of twin pairs profiled at age 10 (n=18) in 
order to investigate whether site-specific DNA methylation differences between MZ twins discordant for 
age-12 psychotic symptoms were also present at this earlier age. Table 2 shows within-pair DMPs at age 
5 nominally associated with psychotic symptoms at age 12 (P<5x10
-5
), with a more extensive list of DMPs 
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(nominal P<0.001) given in supplementary table 5. None of the top-ranked age-10 DMPs (nominal 
P<5x10
-5
) were characterized by significant within-pair differences at age 5 (table 1). There was no 
correlation in effect sizes between ages 5 and 10 for these loci (r=0.09, P=0.76). Next, we examined 
within-pair differences at age 10 at the top-ranked DMPs identified at age 5. Top-ranking DMP 
(cg10377582), located in the POU6F1 gene (Mean ∆β=-0.077, P=3.03x10
-5
), identified in the age-5 
analysis was also nominally significantly hypomethylated at age 10 (Mean ∆β=-0.04, P=0.047). However, 
overall, there was no correlation in effect sizes between ages 5 and 10 for these loci (r=0.2, P=0.57). 
None of the top-ranked DMPs (P<5x10
-5
) at age 5 were associated with schizophrenia in our PFC 
schizophrenia meta-analysis. 
Changes in DNA methylation between ages 5 and 10 in discordant MZ twins 
Finally, we examined CpG sites characterized by psychosis-associated intra-individual changes in DNA 
methylation between ages 5 and 10. For each probe, we calculated the change in DNA methylation from 
age 5 to age 10 (longitudinal ∆β) for each individual and examined the difference in longitudinal ∆β 
between affected twins and their unaffected co-twin. Table 3 lists the top-ranked ∆β between ages 5 and 
10 associated with age-12 psychotic symptoms (P<5x10
-5
), with a more extensive list of DMPs (nominal 
P<0.001) in supplementary table 6. The top-ranked probe (cg15797527), located in the Abelson helper 
integration-1 (AHI1) gene, was characterized by increased DNA methylation from ages 5 to 10 in affected 
twins compared to their unaffected co-twin (longitudinal ∆β=0.084; P=4.30x10
-6
). However, DNA 
methylation at this position was not associated with schizophrenia in our PFC samples (P=0.678). GO 
term enrichment analysis found 67 nominally significant enriched categories for the DMPs (P<0.001) 
identified in the longitudinal analysis (see supplementary table 7 for full gene list), with the top enriched 
GO categories relating to the presynaptic membrane (GO:0042734, P=0.0032) and the perikaryon 
(GO:0043204, P=0.0035). However, no enrichment term remained significant after Bonferroni correction 
for multiple testing. 
Discussion 
This is the first study to assess epigenetic variation in MZ twins discordant for childhood psychotic 
symptoms. We first examined genome-wide patterns of DNA methylation in buccal cell samples collected 
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at age 10. The top-ranked DMP (cg23933044), which is hypomethylated in twins reporting psychotic 
symptoms at age 12 compared to their unaffected co-twin, is located in the promoter regulatory region of 
the protein coding gene C5ORF42 overlapping a number of transcription factor binding sites (TFBSs). 
Interestingly, the same CpG site is significantly hypomethylated in post-mortem PFC samples from 
schizophrenia patients compared with matched control subjects. C5ORF42 encodes a highly conserved 
3,198 amino acid protein whose function is largely uncharacterized, although it is known to interact with 
genes important for neural development, including the p21-activating kinase 1 (PAK1) and the small 
ubiquitin-like modifier 1 (SUMO1).
20
 BioGPS, an online gene annotation resource, indicates that 
C5ORF42 is widely expressed in a variety of tissues, including the brain and peripheral tissues.
21
 Of note, 
mutations in C5ORF42 cause Joubert syndrome, a severe neurodevelopmental disorder,
20,22
 which can 
result in developmental delays similar to those seen in some individuals who have childhood psychotic 
symptoms or are later diagnosed with schizophrenia.
23
 
Several of the other top-ranked DMPs identified at age 10 are located in the vicinity of genes that 
have previously been implicated in neurodevelopment and psychiatric disorders. For example, 
cg08263941, which is hypermethylated in affected twins compared to their unaffected co-twin, is located 
upstream of CHRM2, a gene implicated in memory and cognition and whose function is impaired in many 
neuropsychiatric disorders.
24-26
 Similarly, cg14133557, which is hypermethylated in affected twins 
compared to their unaffected co-twin, is located in the promoter of LPAR1, a gene important for cellular 
signaling; a Lpar1 null mouse model has been shown to exhibit a schizophrenia-like pathology.
27
 
Furthermore, DMPs cg05318275 and cg12252412 are associated with genes encoding two of the 
α2 adrenergic receptors (ADRA1A and ADRA2A, respectively). These receptors have a role in 
regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central 
nervous system and have previously been implicated in psychiatric disorders.
28,29
 Finally, GO enrichment 
analysis highlighted significant enrichment for pathways associated with neurological processes, such as 
establishment of cell polarity and neuron projection development. 
None of the top-ranked DMPs identified at age 10 show significant within-pair differences at age 
5. We therefore examined psychosis-associated intra-individual changes in DNA methylation between 
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ages 5 and 10. The top-ranked longitudinal DMP (cg15797527), which was significantly hypermethylated 
from age 5 to age 10 in the affected twins compared to their unaffected co-twins, is located in the AHI1 
gene. AHI1 is required for both cerebellar and cortical development in humans and has previously been 
associated with schizophrenia,
30-32
 autism,
33
 and Joubert syndrome-related disorders.
34
 Genes annotated 
to the most DMPs between ages 5 and 10 in twins who went on to display psychotic symptoms 
highlighted significant GO term enrichment for neuronal cellular components including the bulbous end of 
neurons (perikaryon) and the presynaptic membrane, suggesting that epigenetic variation at these loci 
may be associated with neuronal dysfunction. Interestingly, previous imaging studies have reported 
dysregulated presynaptic membrane expression of key neurotransmitters in first-episode psychosis.
35
 
Methodological considerations 
Despite the power of the discordant MZ twin approach for epigenetic epidemiology, there are several 
limitations to this study. First, only seven psychotic symptoms were assessed. However, the questions 
used are well-established and have been validated and used previously in studies of psychotic 
phenomena in children.
2,36-39
 Second, we could not ascertain the precise timing of the symptoms, as they 
were not inquired about until age 12. We therefore cannot conclude that the differences identified at age 
10 predate the onset of psychotic symptoms, nor can we exclude the possibility of reverse causality. 
However, age 11-12 is thought to be the youngest age when children can understand the psychosis 
interview and provide valid responses.
1
 Third, our analysis utilized a small cohort of 48 twin children (24 
MZ pairs) and is relatively underpowered to detect small changes in DNA methylation. Although no probe 
reached Bonferroni-corrected levels of significance, DNA methylation studies in other psychiatric 
phenotypes (and complex disorders in general) report similarly small absolute differences, and given the 
known non-independence of DNA methylation across the probes represented on the array,
40
 it is likely 
that conventional methods of global statistical significance are not optimal for these analyses. We also 
therefore calculated empirical P values for each of the top-ranked probes using a permutation testing 
approach as an alternative approach to assess significance.
41
 Fourth, as epigenetic studies cannot be 
performed in the brains of live children, the genome-wide data generated in this study are from peripheral 
buccal cell DNA rather than the brain. However, buccal cells were selected as the most suitable 
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peripheral tissue because they derive from the same embryonic cells as brain tissue (ectoderm) and have 
less cellular heterogeneity compared with blood.
42
 Although there are well-documented tissue-specific 
differences in DNA methylation,
43
 we and others have shown that disease-associated changes in DNA 
methylation can be identified in peripheral tissues.
11-13,17-19,44-47
 Although these might not be directly 
involved in disease pathogenesis, they are of potential use as biomarkers of disease. Furthermore, in this 
study we confirmed disease-associated hypomethylation of our top-ranked DMP (cg23933044) using 
post-mortem PFC samples from schizophrenia patients, indicating that locus-specific methylation patterns 
identified in peripheral tissue may sometimes reflect disease-associated variation in the brain. Other 
DMPs identified in the buccal samples from our twins, however, were not confirmed in post-mortem brain 
tissue. Additionally, given that our sample were only aged 12 we cannot rule out the possibility that the 
unaffected co-twin might develop psychotic symptoms at a later age. 
Technical validation, using bisulfite pyrosequencing, of our top-ranked DMP (cg23933044) was 
not performed in this study. We and others have previously successfully technically validated DNA 
methylation levels obtained from the 450K array using pyrosequencing, thus highlighting the reliability of 
this array.
18,19,48,49
 Moreover, the analytical sensitivity of bisulfite pyrosequencing is ~5–10% for individual 
CpG dinucleotides
50
 and, thus, does not have the sensitivity required to detect small (<5%) changes in 
DNA methylation between cases and controls. Hence, we sought to replicate our DNA methylation 
findings using two independent brain cohorts instead of technically verifying our results. We believe this 
approach is more applicable to the current study given the small changes in DNA methylation (∆β=0.034) 
observed between discordant MZ twins. However, we only used brains from patients diagnosed with 
schizophrenia and although childhood psychotic symptoms have been shown to be highly predictive of 
the later development of schizophrenia
3,36
 they have also been shown to be associated with other mental 
health problems in adulthood
3
 and, thus, exploration of how our findings replicate in the brains of patients 
with other psychiatric disorders would be useful. One final caveat in this study is that chorionicity data 
were not available on these twins; a potential limitation, given that whether or not MZ twins share a 
placenta may influence epigenomic and transcriptional differences mediated by subtle differences in the 
prenatal environment.
51 
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Despite these limitations, this paper provides a useful template for future epigenetic studies of psychiatric 
and behavioral phenotypes. First, employing a discordant twin design allowed us to control for genotype, 
age, sex, paternal age, population cohort effects, and exposure to several shared environmental factors 
(e.g., passive smoking within the home). Second, we utilized longitudinally collected data, which enabled 
us to compare within-individual differences over time and ascertain the temporal ordering of methylation 
differences and emergence of the phenotype. Finally, we attempted to perform cross-tissue replication of 
our peripheral tissue findings in post-mortem brain tissue samples. Incorporating the experimental design 
and analyses utilized in this study would strengthen future research efforts examining the role of 
epigenetic processes in the onset of mental health difficulties. 
Conclusion 
In summary, we present the first evidence that site-specific epigenetic variation may be associated with 
childhood psychotic symptoms in peripheral DNA samples from symptom-discordant MZ twin pairs. The 
top-ranked psychosis-associated DMP (cg23933044) identified in this study was also significantly 
hypomethylated in the prefrontal cortex of adult schizophrenia patients compared to age-matched control 
subjects, suggesting that some peripheral biomarkers of disease may reflect later disease-associated 
variation in the brain. 
 
Materials and Methods 
Study cohort 
Participants were recruited from the Environmental Risk (E-Risk) Longitudinal Twin Study, which tracks 
the development of a birth cohort of 1,116 British twin pairs (n=2,232 individuals). The E-Risk sample was 
drawn from a larger representative birth register of same-sex twins born in England and Wales in 1994-
95.
52
 Full details about the sample are reported elsewhere.
53
 The sample includes 55% MZ and 45% 
dizygotic twin pairs. Sex is evenly distributed within zygosity (49% male). The children were originally 
seen when they were aged 5 and follow-up home visits took place when they were aged 7 (98% 
participation), 10 (96% participation), and 12 (96% participation) years. The Joint South London and 
Maudsley and the Institute of Psychiatry Research Ethics Committee approved each phase of the study 
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(NRES 1997/122). Parents gave informed consent at every phase and children gave assent at the age-12 
assessment phase. 
Measures 
DNA samples 
Buccal cell samples were obtained from children during home visits at ages 5 and 10. Genomic DNA was 
isolated from buccal cells using a standard procedure.
54
 DNA was tested for degradation and purity using 
spectrophotometry and gel electrophoresis prior to methylomic profiling. 
Childhood psychotic symptoms 
When the children were 12 years-old, psychotic symptoms were assessed in a private individual 
structured interview conducted by mental health trainees or professionals.
1,55
 Interviewers had no prior 
knowledge about the child. Seven psychotic symptoms were investigated related to delusions and 
hallucinations using items from the Dunedin Study‘s age-11 interview protocol
36 
and the Avon 
Longitudinal Study of Parents and Children interview.
37,38
 Our protocol took a conservative approach to 
designating a child‘s report as a symptom. First, when a child endorsed any symptom, the interviewer 
probed using standard prompts designed to discriminate between experiences that were plausibly real 
(e.g., ―I was followed by a man after school‖) and potential symptoms (e.g., ―I was followed by an angel 
who guards my spirit‖) and wrote down the child‘s narrative description of the experience. Interviewers 
coded these descriptions 0, 1, or 2, indicating, respectively, ―not a symptom,‖ ―probable symptom,‖ and 
―definite symptom.‖ Second, a psychiatrist expert in schizophrenia, a psychologist expert in interviewing 
children, and a child and adolescent psychiatrist reviewed all the written narratives from the interviews to 
confirm the interviewers‘ codes. Third, experiences limited to the twin relationship (e.g., ―My twin and I 
often know what each other are thinking‖) were coded as ―not a symptom.‖ A dichotomous variable was 
created representing children who reported no definite psychotic symptoms (n=2,002, 94.1%) and those 
who reported at least one definite psychotic symptom (n=125, 5.9%). Of these, 25 MZ twin pairs were 
discordant for the presence of a definite psychotic symptom at age 12, and of these pairs, 16 (64%) were 
male, all were Caucasian and UK-born. None of the twins in this sample took any medications for 
emotional, behavioral, or psychiatric conditions during childhood. 
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Potential confounders 
Internalizing and externalizing problems at age 10 were assessed using the Child Behaviour Checklist in 
face-to-face interviews with mothers
56
 and the Teacher‘s Report Form by mail for teachers.
57
 The 
internalizing problems scale is the sum of items in the withdrawn and anxious/depressed subscales, and 
the externalizing problems scale is the sum of items from the aggressive and delinquent behavior 
subscales. We summed and standardized mothers‘ and teachers‘ reports to create cross-informant 
scales. At age 12, children completed the Children‘s Depression Inventory (CDI),
58
 with scores of 20 or 
more indicating clinically significant depressive symptoms.
59
 
DNA Methylomic Profiling 
Genomic DNA (500 ng) was treated with sodium bisulfite using the EZ-96 DNA Methylation Kit (Zymo 
Research, CA, USA) following the manufacturers‘ protocol. DNA methylation was quantified using the 
Infinium HumanMethylation450 BeadChip array (Illumina, Inc., San Diego, California), as previously 
described.
60 
Each MZ twin pair was processed together throughout the entire experimental procedure to 
minimize potential within-pair batch effects, with all samples processed blind to phenotype. Genome 
Studio software (Illumina, Inc.) was used to extract signal intensities for each probe and perform initial 
quality control (QC). Further QC checks, quantile normalization, and separate background adjustment of 
methylated and unmethylated intensities of type I and II probes were undertaken using the ‗dasen‘ 
function in the R wateRmelon package (available from www.bioconductor.org).
60
 Samples with >5% of 
sites with a detection P value <0.05 or a bead count <3 in >5% of samples were removed from further 
analysis, together with their co-twin. Non-specific probes and probes on the X and Y chromosomes were 
removed.
61,62
 The final analyses included 391,565 probes, and incorporated data from 18 MZ pairs (36 
individual samples) at age 5 and 24 MZ pairs (48 individual samples) at age 10. Polymorphic single 
nucleotide polymorphism (SNP) control probes (n=65) located on the array were used to confirm 
monozygosity for all twin-pairs included in the final analysis. 
Statistical analyses 
We assessed genome-wide patterns of DNA methylation at ages 5 and 10 in buccal cells from twins who 
went on to report psychotic symptoms at age 12, and their unaffected co-twins. Our primary focus was on 
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within-pair DNA methylation differences detected at age 10, as this was the most proximal sampling 
collection point to when psychotic symptoms were assessed at age 12. All statistical analyses were 
performed using R (version 3.1.1). Our primary analyses employed paired t-tests to identify differentially 
methylated positions (DMPs) between affected (1 or more definite psychotic symptoms at age 12) and 
unaffected (no definite psychotic symptoms at age 12) twin children using DNA collected at age 10. The 
beta value (β) is a ratio between methylated probe intensity and total probe intensities (sum of methylated 
and unmethylated probe intensities) and ranges from 0 to 1. Probes were ranked according to p value 
and Q-Q plots assessed to check for P value inflation (see supplementary figure 1A). For the top-
ranked DMPs (nominal P<5x10
-5
), linear regression was performed to adjust β values for internalising and 
externalising problems at age 10, to check that these difficulties were not accounting for any observed 
DNA methylation differences, together with clinically significant depressive symptoms at age 12, to 
ensure that these symptoms were not confounding the phenotypic difference between the twins. Paired t-
tests were used to examine differences in these adjusted β values between affected and unaffected MZ 
twins at age 10 at the top-ranked DMPs (nominal P <5x10
-5
). Analyses were repeated for buccal samples 
collected at age 5. Intra-individual changes in DNA methylation from ages 5 to 10 were calculated 
(longitudinal ∆β) with differences in longitudinal ∆β between affected twins and their unaffected co-twin 
assessed using paired t-tests. An empirical P value was calculated for top-ranked DMPs (P<0.00005) in 
psychosis-discordant twins at age 10 (n=24 twin pairs) and age 5 (n=18 twin pairs) by randomly assigning 
twin status (affected/unaffected) for 10,000 permutations. An empirical P value was calculated by dividing 
the number of permutations, which were at least as significant as the true result (P<0.00005) by the 
number of permutations performed (10,000). 
The specificity of the 10 top-ranked psychosis-associated DMPs was determined by examining 
within-twin DNA methylation differences at these loci in 20 age-matched concordant unaffected control 
MZ twin pairs, with no history of age-12 psychotic symptoms. The average within-twin ∆β, at these loci, 
was calculated using permutation testing (n=1000). Briefly, concordant unaffected twin-pairs were 
randomly assigned to a dichotomous variable [0 (Twin 1) or 1 (Twin 2)] and the within-twin ∆β (beta value 
of Twin 1 – beta value of Twin 2) was calculated for each twin pair at each probe. Next, the average 
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within-twin ∆β was calculated across all twin pairs at each probe, this was repeated 1000 times. The 
average within-twin ∆β was calculated by taking the average of the permutated within-twin ∆β values 
obtained at each DMP of interest. The average within-twin ∆β for the unaffected concordant twins was 
then compared to the average within-twin ∆β calculated from the discordant MZ twins at each probe of 
interest using a two-sample t-test. 
Gene Ontology Term Enrichment Analysis 
Gene ontology (GO) term enrichment analysis was performed on genes annotated (Illumina UCSC gene 
annotation) to the top-ranked DMPs (nominal P<0.001) using the R package GOseqv1.18.1 (downloaded 
from Bioconductor).
63
 GOseq can be used to correct for the number of Illumina 450K probes in each gene 
during GO term enrichment analysis. The number of probes per gene was calculated in our final dataset 
to create a probability weighting function, which was then used in the GO term enrichment analysis.  
 
Post-mortem brain DNA methylation data 
Prefrontal cortex (PFC) post-mortem brain samples were obtained from 20 schizophrenia cases‘ and 23 
non-psychiatric controls‘ adult brains archived in the London Brain Bank for Neurodegenerative Disorders 
(LBBND) and from 18 schizophrenia cases‘ and 15 non-psychiatric controls‘ brains obtained from the 
Douglas Bell-Canada Brain Bank (DBCBB), Montreal (www.douglasbrainbank.ca) as described in Pidsley 
et al.
10
 Subjects were approached in life for written consent for brain banking, and all tissue donations 
were collected and stored following legal and ethical guidelines (NHS 08/MRE09/38; HTA license:12293; 
University of Exeter Medical School Research Ethics Committee:13/02/009). Briefly, genomic DNA was 
isolated using a standard phenol-chloroform extraction protocol. Schizophrenia patients were diagnosed 
by trained psychiatrists according to DSM criteria. Demographic information for the samples is 
summarized in supplementary table 4. Samples were randomized with respect to gender and disease 
status to avoid batch effects throughout all experimental procedures. All microarray pre-processing and 
data normalization was performed as described above. A fixed effects meta-analysis of the two 
independent schizophrenia brain cohorts was performed using the metacont function from the ―meta‖ 
package in R (http://cran.r-project.org/).
64
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Table 1. The top-ranked DMPs at age 10 in monozygotic twin pairs discordant for psychotic symptoms at 
age 12 
  Age 10 Age 5        
Probe 
ID 
Affe
cted 
Twi
n 
Mea
n 
C
o-
T
wi
n 
M
ea
n 
Me
an 
∆β 
P 
valu
e 
Emp
irica
l P 
valu
e*  
M
ea
n 
∆β 
P 
value 
Hg19 Illumin
a Gene 
Annota
tion 
Pr
ob
e 
Ty
pe 
Gene Annotation 
from GREAT 
(Distance from 
TSS) 
cg239
33044 
0.31
5 
0.
34
9 
-
0.0
34 
6.76
E-
07 
<0.0
001 
0.00
8 
0.5
18 
Chr5:372
49909 
C5orf42 II C5orf42 (-380) 
cg141
33557 
0.79
6 
0.
74
2 
0.0
55 
1.65
E-
06 
<0.0
001 
0.01
7 
0.4
02 
Chr9:113
802005 
  II LPAR1 (-1641) 
cg046
61436 
0.79
5 
0.
75
1 
0.0
44 
1.81
E-
06 
0.00
01 
0.02
3 
0.0
57 
Chr15:79
169207 
MORF4
L1 
II MORF4L1 (+4036), 
CTSH (+68212) 
cg115
18839 
0.37
8 
0.
42
8 
-
0.0
51 
8.11
E-
06 
<0.0
001 
-
0.00
4 
0.7
96 
Chr5:176
216711 
  II UNC5A (-20848), 
TSPAN17 (+142324) 
cg165
08913 
0.76
6 
0.
69
8 
0.0
68 
2.25
E-
05 
0.00
06 
0.01
0 
0.6
72 
Chr11:11
609419 
GALNT
L4 
II CSNK2A1 (-234516), 
GALNTL4 (+34141) 
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cg191
15205 
0.89
9 
0.
87
3 
0.0
26 
2.28
E-
05 
0.00
01 
-
0.00
3 
0.7
41 
Chr5:506
2128 
LOC34
0094 
I ADAMTS16 (-78314) 
cg057
64011 
0.88
0 
0.
90
7 
-
0.0
27 
2.55
E-
05 
<0.0
001 
-
0.00
3 
0.8
24 
Chr10:40
9541 
DIP2C II ZMYND11 
(+183608), DIP2C 
(+326066) 
cg264
03608 
0.30
8 
0.
39
6 
-
0.0
88 
2.58
E-
05 
<0.0
001 
0.03
3 
0.1
29 
Chr17:23
19719 
METT1
0D 
II MNT (-15462), 
METTL16 (+95480) 
cg045
76398 
0.74
7 
0.
70
0 
0.0
47 
3.10
E-
05 
<0.0
001 
0.00
2 
0.8
61 
Chr12:13
2262872 
SFRS8 II MMP17 (-50068), 
SFSWAP (+67238) 
cg169
91886 
0.90
3 
0.
88
8 
0.0
15 
3.58
E-
05 
0.00
03 
-
0.00
1 
0.6
89 
Chr6:118
32079 
  I HIVEP1 (-180644), 
C6orf105 (-52800) 
cg080
61902 
0.84
8 
0.
81
8 
0.0
29
8 
3.71
E-
05 
0.00
01 
0.02
5 
0.1
06 
Chr19:40
169418 
LOC40
0696 
II LGALS14 (-25527), 
LGALS16 (+22861) 
cg274
18099 
0.74
4 
0.
69
0 
0.0
54
1 
3.92
E-
05 
<0.0
001 
-
0.00
9 
0.7
57 
Chr16:88
941395 
CBFA2
T3 
II PABPN1L (-8328), 
CBFA2T3 (+102108) 
cg205
46928 
0.06
8 
0.
05
7 
0.0
10
7 
4.47
E-
05 
<0.0
001 
0.00
1 
0.7
67 
Chr8:271
67985 
PTK2B;
TRIM35 
II TRIM35 (+848) 
Note. Ranked by age-10 P value. ∆β, difference in DNA methylation; DMPs, differentially methylated 
positions; GREAT, Genomic Regions Enrichment of Annotations Tool; Hg19, Human Genome build 19; 
TSS, transcription start site. * An empirical P value was calculated by dividing the number of permutations 
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that are at least as significant as the true result (P<0.00005) by the number of permutations performed 
(10,000). 
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Table 2. The top ranked DMPs at age 5 in monozygotic twin pairs discordant for psychotic symptoms at 
age 12 
  Age 5  Age 10         
Probe 
ID 
Aff
ect
ed 
Twi
n 
Me
an 
C
o-
T
wi
n 
M
ea
n 
M
ea
n 
∆β 
P value Emp
irica
l P 
valu
e* 
 M
ea
n 
∆β 
P 
va
lu
e 
Hg19 Illumin
a Gene 
Annota
tion 
Pro
be 
Typ
e 
Gene 
Annotation 
from GREAT 
(Distance from 
TSS) 
cg150
31661 
0.1
50 
0.
13
0 
0.02
0 
1.26
E-
05 
0.000
1 
 -
0.
00
1 
0.80
5 
Chr1:2383
23226 
FMN
2 
I FMN2 (+1419), 
GREM2 (+518858) 
cg264
32347 
0.0
82 
0.
06
3 
0.01
8 
1.87
E-
05 
0.000
1 
 0.
00
2 
0.50
8 
Chr6:3081
8615 
FLO
T1 
I FLOT1 (-184) 
cg113
56706 
0.0
70 
0.
06
1 
0.01
0 
1.95
E-
05 
<0.00
01 
 0.
00
6 
0.11
3 
Chr20:604
240 
SCR
T2 
I SCRT2 (+582) 
cg160
11679 
0.1
16 
0.
09
4 
0.02
2 
2.59
E-
05 
0.000
2 
 -
0.
00
8 
0.19
0 
Chr1:8549
7983 
C1orf
52 
I SYDE2 (-58668), 
BCL10 (+17191) 
cg214 0.8 0. 0.01 2.64 0.000  0. 0.07 Chr7:1585   II ESYT2 (-196875), 
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80740 99 88
3 
6 E-
05 
2 01
5 
9 11954 VIPR2 (+118455) 
cg103
77582 
0.4
43 
0.
52
0 
-
0.07
7 
3.03
E-
05 
<0.00
01 
 -
0.
04
0 
0.04
7 
Chr12:498
99061 
POU
6F1 
I POU6F1 (-20845), 
DAZAP2 
(-19713) 
cg240
85426 
0.8
63 
0.
83
9 
0.02
4 
3.05
E-
05 
0.000
1 
 0.
00
6 
0.50
6 
Chr12:458
69545 
  II AMIGO2 (-109545), 
FAM113B 
(-26726) 
cg030
44239 
0.0
72 
0.
08
0 
-
0.00
8 
3.15
E-
05 
<0.00
01 
 -
0.
00
3 
0.52
9 
Chr3:1395
49743 
MRA
S 
II MRAS (-454) 
cg065
47771 
0.0
44 
0.
05
2 
-
0.00
8 
3.34
E-
05 
0.000
1 
 -
0.
00
2 
0.36
6 
Chr11:433
36969 
TTC1
7 
I TTC17 (-41) 
cg146
59771 
0.1
38 
0.
11
4 
0.02
4 
3.59
E-
05 
<0.00
01 
 0.
00
5 
0.39
1 
Chr2:2316
25606 
  I PSMD1 (-4215) 
cg243
91460 
0.5
25 
0.
46
2 
0.06
2 
4.12
E-
05 
<0.00
01 
 -
0.
00
5 
0.79
3 
Chr7:7892
2102 
MAG
I2 
I MAGI2 (-1277) 
Note. Ranked by age-5 P value. ∆β, difference in DNA methylation; DMPs, differentially methylated 
positions; MZ, monozygotic; GREAT, Genomic Regions Enrichment of Annotations Tool; TSS, 
transcription start site. * An empirical P value was calculated by dividing the number of permutations that 
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are at least as significant as the true result (P<0.00005) by the number of permutations performed 
(10,000). 
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Table 3. The top ranked CpG sites that show changes in DNA methylation levels between ages 5 and 
age 10 in the monozygotic twins discordant for psychotic symptoms at age 12 
Probe 
ID 
Affec
ted 
Twin 
Mean 
Co-
Twi
n 
Me
an 
Mean 
change 
in 
longitu
dinal ∆β 
P 
value 
Hg19 Illumin
a Gene 
Annota
tion 
Pro
be 
Typ
e 
Gene Annotation from 
GREAT (Distance from 
TSS) 
cg1579
7527 
0.044 -
0.0
40 
0.084 4.30E
-06 
Chr6:1358
14781 
AHI1 II AHI1 (+4121), MYB 
(+312329) 
cg1005
2038 
0.040 -
0.0
36 
0.076 7.91E
-06 
Chr3:1962
93939 
WDR53 II FBXO45 (-1785) 
cg2740
3609 
-
0.016 
0.0
28 
-0.044 1.14E
-05 
Chr2:1110
1403 
  I PQLC3 (-194136), KCNF1 
(+49341) 
cg1155
6416 
-
0.034 
0.0
41 
-0.074 1.35E
-05 
Chr2:1918
79252 
STAT1 I STAT1 (-277) 
cg1356
7282 
0.023 -
0.0
43 
0.066 1.40E
-05 
Chr6:1496
53214 
MAP3K
7IP2 
II TAB2 (+13779), ZC3H12D 
(+152933) 
cg1959
9395 
0.066 -
0.0
07 
0.073 1.40E
-05 
Chr19:383
7031 
ZFR2 II MATK (-50617), ZFR2 
(+31995) 
cg2699
8693 
-
0.024 
0.0
13 
-0.036 1.54E
-05 
Chr6:1328
34590 
STX7 II STX7 (-254) 
cg1905 0.037 - 0.089 1.76E Chr2:1138 IL1F5 II IL1F10 (-5456), IL36RN 
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0351 0.0
52 
-05 20090 (+3406) 
cg1826
0625 
-
0.011 
0.0
15 
-0.027 1.87E
-05 
Chr5:4295
1192 
  I SEPP1 (-139169), C5orf39 
(+89254) 
cg1429
7966 
-
0.003 
-
0.0
57 
0.055 2.40E
-05 
Chr9:3510
1708 
STOML
2 
II PIGO (-5163), STOML2 
(+1445) 
cg0252
4205 
-
0.038 
0.0
54 
-0.091 2.51E
-05 
Chr6:1675
59851 
  I GPR31 (+11467), CCR6 
(+34557) 
cg1273
0562 
-
0.025 
0.0
41 
-0.067 2.87E
-05 
Chr11:449
27876 
TSPAN
18 
II TP53I11 (+44731), 
TSPAN18 (+141901) 
cg2282
7324 
-
0.017 
0.0
22 
-0.039 3.31E
-05 
Chr2:3361
2876 
LTBP1 II RASGRP3 (-126065), 
LTBP1 (+440508) 
cg2661
3742 
0.015 -
0.0
53 
0.068 3.42E
-05 
Chr19:142
25000 
PRKAC
A 
II SAMD1 (-23769), PRKACA 
(+3558) 
cg0335
9468 
0.014 -
0.0
08 
0.023 3.62E
-05 
Chr8:2624
0463 
BNIP3L I BNIP3L (-59) 
cg2536
7206 
0.038 -
0.0
20 
0.059 3.82E
-05 
Chr8:1422
39055 
SLC45A
4 
I SLC45A4 (-383) 
cg0391
6630 
0.053 -
0.0
40 
0.092 4.01E
-05 
Chr10:450
65415 
  II TMEM72 (-341348), 
CXCL12 (-184871) 
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Note. Ranked by P value (P<5x10
-05
). ∆β, difference in DNA methylation; DMPs, differentially methylated 
positions; GREAT, Genomic Regions Enrichment of Annotations Tool; Hg19, Human Genome build 19; 
TSS, transcription start site. 
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Figure 1. A, Graphs showing the difference in DNA methylation (∆β) at age 10 between each pair of 
monozygotic (MZ) twins discordant for psychotic symptoms at age 12 (affected twin – unaffected co-twin) 
for each of the ten top-ranked probes. Mean within-twin pair ∆β across all 24 MZ twin-pairs is highlighted 
in red. Consistent within-twin pair differences in DNA methylation at age 10 are observed across 
discordant MZ twin pairs (n=24) at the ten top-ranked differentially methylated positions (DMPs). B, 
Graph showing average within-twin beta difference (∆β) of psychosis-discordant MZ twins at age 10 and 
the age-matched concordant unaffected MZ twins (20 twin pairs). DNA methylation levels were available 
for 9/10 psychosis-associated DMPs. Average within-twin differences in DNA methylation are significantly 
larger (P<0.005 for all comparisons) at nine of the top-ranked DMPs in psychosis-discordant twins 
compared to twins concordant for no psychotic symptoms. Between groups comparison of mean within-
twin beta differences was examined using a two-sample T test. Error bars represent +/- the standard 
deviation of the mean within-twin pair ∆β. 
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Figure 2. The top-ranked differentially methylated probe (cg23933044) is consistently hypomethylated at 
age 10 in monozygotic (MZ) twins with age-12 psychotic symptoms compared to their unaffected co-twin, 
and is also hypomethylated in adult prefrontal cortex (PFC) post-mortem tissue from schizophrenia 
patients compared to matched control subjects. A, CpG site, cg23933044, is consistently hypomethylated 
at age 10 across 24 MZ twins discordant for psychotic symptoms at age 12 (P=6.76x10
-7
) B, Comparison 
of DNA methylation at cg2393304 in 38 schizophrenia and 38 control post-mortem PFC samples confirms 
psychosis-associated hypomethylation (P=0.0005). C, Forest plot depicting a fixed-effects meta-analysis 
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of a comparison of two independent schizophrenia brain cohorts: London Brain Bank for 
Neurodegenerative Disorders (LBBND) and Douglas Bell-Canada Brain Bank (DBCBB). Squares: mean 
beta difference, Horizontal lines: 95% confidence intervals (CI): Blue diamond: overall mean beta 
difference for meta-analysis, SE: Standard Error, df: degrees of freedom, H P value: Heterogeneity P 
value, Q: chi-squared statistic, I
2
: percentage of the variability in effect estimates that is due to 
heterogeneity rather than sampling error. 
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